BeiGene is developing a pipeline of oral small molecules and monoclonal antibodies to fight cancer. Get up to date with the BeiGene hematology pipeline and clinical trials.
Poster presented at ASH 2022 evaluating new therapeutic approaches for patients with B-cell malignancies who received prior BTKi treatment and became intolerant.
Poster presented at ASH 2022 describing the potential for combining BCL2i and BTKi in patients with non-Hodgkin’s lymphoma (NHL), including separate cohorts for mantle cell lymphoma (MCL) and Waldenström’s macroglobulinemia (WM).
A summary of the latest developments from 12 studies in BTK inhibition in B-cell malignancies presented at EHA2022.
The Satellite Symposium at BSH 2022 provided expert insights into treatment options in Waldenström’s macroglobulinemia (WM), the emerging role of BTKis in WM, and BTKi-associated adverse events and their management.